Myomectomy during pregnancy: an obstetric overview

Minerva Obstet Gynecol. 2021 Oct;73(5):646-653. doi: 10.23736/S2724-606X.21.04676-5. Epub 2021 May 14.

Abstract

Introduction: Uterine fibroids (UFs) are the most common benign disease affecting female reproductive system, and occurring in 20-40% of women, and in 10% of pregnancies. The aim of the investigation was to summarize evidence about the management and treatment of UFs and related complications in pregnancy.

Evidence acquisition: A literature review was performed using scientific databases, including all case report and case series, using a combination of key words related to the problem exposed. Data about gestational age at diagnosis, maximum fibroids diameter, type of surgery and gestational age at surgery, delivery and perinatal outcome were collected. Two clinical cases were also included.

Evidence synthesis: Sixty-six articles were selected, and 199 patients were included. In 76% of patients the gestational age at myomectomy was lower than 20 weeks, in 85% laparotomic surgery was chosen, in 41% of cases the maximum fibroid diameter was between 7-20 cm, in 41% of pregnancies the route of delivery was the Cesarean section. In the eight percent of cases there was a complication given by miscarriage, fetal demise or neonatal death.

Conclusions: Myomectomy is a feasible procedure in those pregnancies complicated by symptomatic fibroids, though surgery in pregnancy is associated with an increased risk of obstetric complications.

Publication types

  • Review

MeSH terms

  • Abortion, Spontaneous* / epidemiology
  • Cesarean Section / adverse effects
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Leiomyoma* / surgery
  • Pregnancy
  • Uterine Myomectomy* / adverse effects
  • Uterine Neoplasms* / surgery